Shots:
- The company reported the results of an expanded access trial for Zofin in patients with COVID-19 which was conducted in Houston, TX
- The trial met EPs for safety & efficacy i.e., improved pulmonary opacities in chest X-rays which showed 83% of patients had normal lung imaging, indicated complete recovery @30 days treatment, improved biomarker levels vs respective control with p-values, mitigated mild and moderate symptoms, was well tolerated with no AEs
- The company will submit this data to FDA for a requested amendment to their approved IND to perform a PBO-controlled P-II clinical trial and also plans to submit results for scientific peer review & publication
Click here to read full press release/ article | Ref: Business Wire | Image: BioInformant
The post Organicell Reports Results of Expanded Access Trial for Zofin to Treat Mild to Moderate COVID-19 first appeared on PharmaShots.
